InterveXion was founded in Little Rock, AR in 2004 with the goal of commercializing immuno-therapies for treating drug abuse. We are a limited liability company with four members and two full time employees. Ownership is closely held by the founders and the University of Arkansas for Medical Sciences (UAMS). Currently, the company occupies office and laboratory space in the UAMS BioVentures Building on the UAMS campus.
The technology behind our products is licensed from the UAMS. Funding for our progress has come from the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) in the form of research grants. These grants have enabled us to advance our anti-METH chimeric antibody through a first in human Phase 1a clinical trial in healthy volunteers.
InterveXion plans to remain focused on the development of new antibody-based therapies for poorly treated or untreated disease targets. Our strategy is to prove the safety and efficacy of our medications through FDA-approved clinical trials, most likely ending with Phase 1b or 2, and then partner the products. To reach this point, InterveXion has identified capable contract organizations to which manufacturing, GLP-compliant toxicology testing, and clinical trials are being outsourced. Assay development work, bioequivalence studies, and regulatory submission preparations are being conducted by InterveXion with some laboratory studies performed at the UAMS.